Anneleen Daemen
Executive Director - Translational Medicine ORIC Pharmaceuticals
Dr. Anneleen Daemen is Executive Director of Translational Medicine at ORIC Pharmaceuticals, where she drives biomarker development and precision medicine strategies for oncology programs. She has over two decades of experience at the intersection of translational research, bioinformatics, and drug development, with a strong focus on harnessing cancer heterogeneity to inform clinical strategy and improve patient outcomes.
Before joining ORIC, Dr. Daemen was a group leader in Computational Biology at Genentech, where she partnered across research and clinical development to shape oncology programs from discovery through late-stage trials. Her leadership contributed to advancing biomarker-driven approaches, understanding drug mechanisms, and addressing resistance in cancer treatment.
She completed her postdoctoral work at Lawrence Berkeley Lab and UCSF, where she identified a DNA-repair deficiency signature predictive of PARP inhibitor response, validated in the I-SPY2 breast cancer trial. Dr. Daemen has authored more than 80 peer-reviewed publications.
Seminars
- Demonstrating how broader ctDNA panels extend beyond single-gene tracking in advanced cancer, as a surrogate readout of clinical efficacy and to reveal tumor heterogeneity and evolving drivers of resistance
- Lessons from applying methylation-based sequencing approaches in oncology trials, including challenges in data interpretation and reporting
- Opportunities and limitations of integrating fragmentomics insights derived from methylation data to complement response monitoring in advanced disease
